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Available online 5 July 2016Background: TheMedtronic Evolut R (EVR) is a novel transcatheter heart valve designed to allow precise implan-
tation at the intended position and to minimize prosthesis dysfunction as well as procedural complications. Our
aimwas to compare short-term functional and clinical outcomes of the new EVRwith the establishedMedtronic
CoreValve (CV) system.
Methods and results:Of 151 patients undergoing transfemoral transcatheter aortic valve implantationwith a self-
expanding valve at our institution between January 2013 and January 2016, 86 were treated with EVR and 65
with CV. Patients treated with EVR had a signiﬁcantly lower rate of more-than-mild aortic regurgitation and a
higher rate of device success. Recapture maneuvers to optimize valve deployment were performed in 22.1% of
the EVR procedures. Transvalvular post-procedural gradients were slightly higher in the EVR group, while no
differences were observed in the incidence of safety endpoints at 30 days, vascular complications, or need for
permanent pacemaker implantation following asystole or complete atrioventricular block.
Conclusions: These initial single-center experience data on the short-term outcomes after EVR valve implantation
show a substantially reduced rate ofmore-than-mild paravalvular regurgitation and higher device success, while
30-day safety outcomes were similar to the CV system. Clinical outcome data from long-term follow-up and
larger scale multicenter experience are now necessary.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Paravalvular leak1. Introduction
Transcatheter aortic valve implantation (TAVI) has emerged as the
treatment of choice for symptomatic aortic stenosis in patients at high
risk for conventional surgical valve replacement. The Medtronic
CoreValve (CV), with leaﬂets made from porcine pericardium sutured
into a self-expanding nitinol frame, was the ﬁrst commercially available
self-expanding TAVI system. TheUSPivotal Trial showed excellent long-
term outcomes after CV implantation in patients classiﬁed as high-risk
for surgical aortic valve replacement [6]. Despite the generally low
TAVI complication rates for such high-risk patient collective, several
important and prognosis relevant issues including paravalvular leaksrdiologie 1, Universitätsmedizin
e (E. Schulz).
eliability and freedom from bias
ould be considered as joint ﬁrst
land Ltd. This is an open access articl[9], access site bleeding [3] or valve dislocation during deployment lim-
ited the procedural success of ﬁrst generation TAVI prosthesis. To tackle
these issues, the Evolut R (EVR) with the EnVeo R delivery catheter was
introduced in 2014. This second generation prosthesis allows reposi-
tioning after implantation, has a lower delivery proﬁle and has an
extended sealing skirt to reduce the incidence of paravalvular
leaks (Fig. 1).
We herein report a single-center experience with the EVR TAVI
system in 86 patients, and compare short-term functional and clinical
performance with this device with historical data using the established
CV TAVI system.
2. Materials and methods
2.1. Patient characteristics and procedural planning
Between January 2013 and January 2016, a total of 151 consecutive
patients received a self-expandable transcatheter aortic valve implanta-
tion in the native annulus with either the Medtronic CV or EVRe under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Compared to the traditional Medtronic CoreValve® prosthesis (left side), new
features of the Medtronic Evolut R™ (right side) include a new design of the nitinol
frame with a lower height and an extended sealing skirt (© Medtronic).
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self-expandable TAVI prostheses that were implanted during the same
period included the Edwards Sapien XT/Sapien 3 (n = 226) and the
Direct Flow Medical Valve (n= 59). Only patients who had symptom-
atic severe aortic valve stenosis, with an aortic valve area (AVA) of
b1.0 cm2 (conﬁrmed by both echocardiography and invasive record-
ings)were treated. All patients were evaluated by our center'smultidis-
ciplinary Heart Team, and TAVI was generally recommended in the
presence of additional risk factors contributing to increased risk for
conventional surgical valve replacement according to current guidelines
[10]. Demographic characteristics aswell as clinical and procedural data
and echocardiographic parameters were prospectively documented in
our center's dedicated database as part of the national quality control
requirements. Baseline demographics are shown in Table 1. All patients
had a diameter of the common femoral artery of N6 mm (N5 mm for
EVR) and were considered suitable for transfemoral vascular access.
Prior to valve replacement, coronary angiography was performed in
all patients to rule out or treat relevant coronary artery disease.
Sizingwas performedwith ECG-triggeredmultislice CT scanwith con-
trast infusion or alternatively (for patients who could not undergo con-
trast CT examination e.g. due to advanced stage renal impairment) withTable 1
Baseline patient characteristics.
CoreValve Evolut R p-value
Number of patients 65 86
Age [years] 84.2 ± 0.5 82.9 ± 0.8 0.19
Female 46 (70) 59 (69) 0.91
log. EuroScore 32 ± 0.5 27.4 ± 0.7 0.06
Body mass index [kg/m2] 27.3 ± 0.6 26.9 ± 0.7 0.7
NYHA class 0.25
III 48 (73) 47 (55)
IV 9 (14) 18 (21)
Diabetes mellitus 24 (36) 28 (33) 0.54
End stage renal failure 1 (1) 2 (2) 0.85
Coronary artery disease 38 (58) 56 (65) 0.69
Previous myocardial infarction 11 (17) 14 (16) 0.47
Previous PCI 11 (17) 29 (34) 0.03
History of cardiac surgery 8 (12) 14 (16) 0.61
Peripheral artery disease 7 (11) 15 (17) 0.57
Neurological dysfunction 8 (12) 21 (24) 0.13
Pulmonary disease 9 (14) 11 (13) 0.93
Atrial ﬁbrillation 16 (24) 28 (33) 0.09
Permanent pacemaker 9 (14) 8 (9) 0.78
Values are mean ± standard error of mean or n (%).3D transesophageal echocardiography. A dedicated software (3mensio)
was used to analyze CT-derived annulus area and diameters, height of
the coronary ostia and the degree of valvular/annular calciﬁcation. In
order to assess the congruence between the native aortic valve annulus
and the prosthesis, the “cover index”was calculated as 100× ([prosthesis
([prosthesis diameter− annulus diameter] / prosthesis diameter) [2].
2.2. TAVI procedure
During the procedure, all patients were under general anesthesia
and received transesophageal echocardiography for procedural
guidance and immediate assessment of paravalvular leakages. In
addition, hemodynamic assessment by simultaneous measurements of
left ventricular (LV) and aortic root pressure was performed before
and after valve implantation. All procedures were performed using the
transfemoral route. To streamline the interventional treatment of
possible vascular complications, a crossover maneuver was done in all
patients with the positioning of a 0.018″ guidewire in the superﬁcial
femoral artery inserted from the contralateral side. Vascular access
site closure was generally achieved with 2 Proglide devices (Abbott
Vascular, Abbott Park (IL), USA).
2.3. Medtronic CoreValve and Evolut R transcatheter valve system
Both the CV and the EVR prosthesis feature a self-expandable nitinol
frame with sutured leaﬂets made from porcine pericardium (Fig. 1). A
sealing skirt slightly cranial to the native annulus was added to prevent
paravalvular leak.When implanted in the correct position, the prosthet-
ic leaﬂets are located in a supra-annular position. Major differences of
the new generation EVR prosthesis include the option to recapture
and reposition the valve, a smaller delivery proﬁle (18F outer diameter
for EVR when used with EnVeo R inline sheath; 22F outer diameter of
the sheath generally required for the CV system), an extended sealing
skirt, a more cylindrical shape of the lower part and more consistent
radial force of the nitinol frame, as previously reported [5]. All EVR
prostheses were implanted with the inline sheath and did not require
the use of an additional 18F sheath.
2.4. Outcome measures
Overall patient outcome was subdivided in implantation data,
procedural outcomeand early safety clinical outcome. During theproce-
dure, implantation depth was determined angiographically at the pre-
speciﬁed optimal angulation with a perpendicular view of all 3 cusps
of the native aortic valve. Hemodynamic assessment included record-
ings of the peak-to-peak gradient and calculation of the aortic regurgita-
tion index [9]. Aortic regurgitation was additionally analyzed by aortic
root angiography as described [8].
Procedural outcome assessment included procedure-related
complications such as coronary obstruction, annular rupture, major
vascular complications, ventricular perforation and intraprocedural
death. In addition, echocardiography was used to determine the post-
procedural transvalvular gradient and degree of aortic regurgitation.
Device success was deﬁned according to the VARC-2 criteria [4] as the
absence of procedural mortality, positioning of a single valve in the
correct anatomic position, and proper valve performance (mean
gradient b20 mm Hg, no moderate or severe aortic regurgitation).
In order to assure reproducibility, all hemodynamic variables were
consistently evaluated by a standardized protocol: pressure recordings
were observed for at least 30 s until a stable signal without artifacts
was obtained. Gradient analyses were done from at least 5 consecutive
beats with simultaneous recordings of left-ventricular and aortic
pressure after zero balance. With respect to angiographic and echocar-
diographic quantiﬁcation of paravalvular aortic regurgitation, all
recordings were independently analyzed by 2 interventional cardiolo-
gists with broad experience in echocardiography. If the grading of aortic
Table 3
Implantation data.
CoreValve Evolut R p-Value
Valve size, mm
23 2 (3) 1 (1)
26 28 (42) 22 (26)
29 33 (50) 63 (73)
31 2 (3) n.a.
Aortic regurgitation by angiography 0.001
None/trace 20 (34) 48 (60)
54 E. Schulz et al. / IJC Heart & Vasculature 12 (2016) 52–56regurgitation was not consistent, an additional cardiologist was
consulted for ﬁnal assessment.
Early safety outcome was a composite of all cause mortality, stroke,
life-threatening bleeding, acute kidney injury stage 2–3, coronary artery
obstruction, major vascular complication and valve-related dysfunction
requiring repeat procedure within 30 days after the procedure. The
incidence of postprocedural pacemaker implantations was categorized
according to the indication (asystole, 2nd or 3rd degree atrioventricular
block).
2.5. Statistical analysis
Continuous variables are presented as mean ± standard error
of mean, and signiﬁcancewas tested by an unpaired t-test. Discrete var-
iables are displayed as counts and percentages and were compared by
using Pearson's Chi2 test. Signiﬁcance was assumed for p-values b 0.05.
3. Results
3.1. Baseline characteristics
A total of 151 patients received implantation of either theMedtronic
CV (n = 65) or Medtronic EVR (n = 86) at our institution between
January 2013 and January 2016. Given the availability of the new EVR
sizes (26 mm & 29 mm) in early 2015, these TAVI prostheses were
implanted from February 2015 to January 2016, whereas the CV
bioprostheses were implanted between January 2013 and February
2015. Other than for a difference in history of coronary intervention
(CV 16.7% vs. EVR 33.7%; p = 0.03), patient characteristics including
age, logistic EuroScore, body mass index and additional risk factors
were comparable between both groups as shown in Table 1.
The severity of aortic valve disease was comparable in both
groups, including similar transvalvular gradients, left ventricular
ejection fraction and pulmonary artery pressure in transthoracic
echocardiography (Table 2).
For procedural planning, multislice CT scans with contrast infusion
(n = 118) or 3D transesophageal echocardiography (n = 33) were
performed, showing similar geometry of the aortic annulus with no
difference in the degree of annular calciﬁcation between groups
(Table 2). Since the smaller proﬁle of the EVR delivery catheter allowed
transfemoral treatment of patients with smaller common femoral arter-
ies, the diameter of the entry vessel was signiﬁcantly smaller in EVR
treated patients (CV 8.0 mm vs. EVR 6.8 mm; p b 0.0001).
3.2. Implantation data
The percentage of predilation (CV 89.2% vs. EVR 86.0%; p= 0.98) as
well as postdilation (CV 21.3% vs. EVR 16.5%; p= 0.39) was similar in
both groups. When compared to CV, a key feature of the EVR is theTable 2
Baseline echocardiography & CT data.
CoreValve Evolut R p-Value
LVEF [%] 48.0 ± 1.3 50.5 ± 1.0 0.12
AV peak gradient [mm Hg] 70 ± 3.3 68 ± 3.1 0.68
AV mean gradient [mm Hg] 45.6 ± 2.2 42.9 ± 2.1 0.41
Aortic valve area [cm2] 0.65 ± 0.02 0.70 ± 0.02 0.93
Regurgitation (moderate/severe)
Aortic valve 11 (17) 18 (21) 0.83
Mitral valve 23 (35) 32 (38) 0.60
Tricuspid valve 12 (18) 27 (31) 0.14
Systolic pulmonary artery pressure [mmHg] 40.5 ± 1.8 43.9 ± 1.5 0.18
Annulus area (CT) [mm2] 441.2 430.3 0.37
Annulus diameter (CT, area derived) [mm] 23.6 ± 0.26 23.4 ± 0.16 0.45
Presence of annular calciﬁcation (CT) 12 (35) 13 (41) 0.78
Access site artery diameter (CT) [mm] 8.0 6.8 b0.0001
Values are mean ± standard error of mean or n (%).option to fully recapture and to reposition the valve during deployment.
This maneuver was performed in 22.1% of EVR treated patients, mostly
due to an initially deep (ventricular) positioning of the valve. There
were 2 cases of a supra-annular valve position in the CV treated patient
group requiring the implantation of a second valve, and none in the EVR
group. In addition, the option to recapture allowed a less ventricular
implantation depth at the non-coronary cusp (CV 5.3 mm vs. EVR
4.0 mm, p= 0.03). Immediate hemodynamic and aortic root angiogra-
phy as well as echocardiographic assessment was done in all patients,
showing a lower incidence of mild to moderate aortic regurgitation in
the EVR group (Tables 3, 4, Fig. 2), and an aortic regurgitation index of
21.3 for CV and 24.9 for EVR treated patients (p = 0.04). In contrast,
transvalvular gradients by simultaneous invasive recordings after
implantation were slightly higher in the EVR group (CV 4.9 mm Hg vs.
EVR 8.9 mm Hg; p = 0.0003), possibly due to a higher degree of
oversizing in the EVR group as indicated by an increased cover index
(CV 15.3 vs. EVR 17.1; p= 0.01).
3.3. Procedural outcome
Despite our high-risk patient collective with a mean logistic
EuroScore N25% in both groups (Table 1), there was no procedural
mortality in either group (Table 4). One patient in the EVR group
developed a signiﬁcant pericardial effusion after implantation.
Pericardiocentesis showed hemorrhage due to left ventricular perfora-
tion by the guidewire, requiring conversion to open chest surgery.
There were no other procedure related acute events in both groups
(Table 4). Vascular complications occurred in 12.1% in CV treated vs.
7.0% in EVR treated patients (p = 0.35). In the EVR group, all of these
were resolved by implantation of a covered stent and in the CV group
3 patients (4.5%) underwent surgical repair. The lower delivery proﬁle
of the EVR allowed transfemoral access despite challenging anatomies
with smaller access site vessel diameter as compared to the CV group.
As a consequence, the sheath to femoral artery ratio (SFAR) [3] was
comparable in both groups (CV 0.96 vs. EVR 0.91).
Device success was signiﬁcantly higher with EVR (CV 81.8% vs. EVR
98.8%; p = 0.0009), mainly driven by the implantation of a second
valve (n = 2) and more cases of more-than-mild residual moderateMild 34 (58) 32 (40)
Moderate 5 (8) 0 (0)
Severe 0 (0) 0 (0)
Balloon pre-dilation 58 (89) 74 (86) 0.98
Balloon post-dilation 14 (22) 14 (16) 0.39
Implantation depth NCC [mm] 5.3 ± 0.53 4.0 ± 0.28 0.03
Implantation depth LCC [mm] 6.9 ± 0.43 6.3 ± 0.28 0.25
Peak-to-peak gradient pre-TAVI [mm Hg] 49.8 ± 4.3 51.8 ± 3.2 0.73
peak-to-peak gradient post-TAVI [mm Hg] 4.9 ± 0.7 8.9 ± 0.6 0.0003
Implantation of N1 valve 2 (3) 0 (0)
Aortic regurgitation index 21.3 ± 1.0 24.9 ± 1.1 0.04
Cover index 15.3 ± 0.56 17.1 ± 0.33 0.01
Contrast amount [ml] 149.6 ± 7.8 155.9 ± 5.7 0.59
Fluoroscopy time [min] 29.0 ± 1.8 25.3 ± 1.2 0.06
Recapture during valve implantation n.a. 19 (22)
1 full recapture n.a. 10 (12)
2 full recaptures n.a. 9 (10)
Sheath to femoral artery ratio 0.96 0.91 0.15
Conversion to surgery 0 (0) 1 (3) 0.62
Values are mean ± standard error of mean or n (%).
Table 4
Procedural outcome.
CoreValve Evolut R p-Value
Procedural mortality 0 (0) 0 (0)
Coronary obstruction 0 (0) 0 (0)
Annular rupture 0 (0) 0 (0)
LV perforation 0 (0) 1 (3) 0.62
Aortic regurgitation by echocardiography 0.0002
None/trace 24 (38) 52 (62)
Mild 30 (48) 32 (38)
Moderate 9 (14) 0 (0)
Severe 0 (0) 0 (0)
AV peak gradient [mm Hg] 12.8 ± 0.8 16.2 ± 0.9 0.016
AV mean gradient [mm Hg] 6.9 ± 0.4 8.3 ± 0.4 0.032
Minor vascular complications 8 (12) 6 (7) 0.35
Implantation of covered stent 5 (8) 6 (7)
Surgical repair 3 (4) 0 (0)
Device success (VARC-2) 54 (82) 85 (99) 0.0009
Values are mean ± standard error of mean or n (%).
Table 5
Early safety clinical outcome.
CoreValve Evolut R p-Value
Early safety endpoint at 30 days (VARC-2) 1 (1) 1 (3) 0.62
All cause mortality 1 (1) 0 (0) 0.86
All stroke 0 (0) 0 (0)
Life-threatening bleeding 0 (0) 0 (0)
Acute kidney injury stage 2–3 0 (0) 0 (0)
Coronary artery obstruction 0 (0) 0 (0)
Major vascular complication 0 (0) 1 (3) 0.62
Valve-related dysfunction requiring
repeat procedure
0 (0) 0 (0)
New pacemaker implantation by indication
Asystole 1 (1) 3 (3) 0.85
2nd/3rd degree AVB 5 (8) 8 (9) 0.97
Postprocedural hospital stay [days] 9.3 ± 0.6 8.4 ± 0.7 0.35
Acute kidney injury stage 1 (VARC-2) 2 (3) 0 0.34
Values are mean ± standard error of mean or n (%).
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accordancewith the invasive recordings, echocardiographic assessment
of valvular function on days 2–5 showed higher transvalvular gradients
in the EVR group (mean gradient CV 6.9mmHgvs. EVR 8.3mmHg; p=
0.032). Conversely, the presence of more-than-mild residual aortic
regurgitation was lower in the EVR group (Table 4).
3.4. Early safety outcome
With respect to VARC-2 safety endpoints at 30 days, there were no
signiﬁcant differences between both valve types as shown in Table 5.
In particular, the incidence of new pacemaker implantations following
asystole or third degree AV block was similar in both groups (CV 9.1%
vs. EVR 12.8%), while more patients in the CV group had a previously
implanted pacemaker (Table 1).
4. Discussion
TheMedtronic CV is the prototype of a self-expanding, transcatheter
aortic bioprosthesis with excellent long-term clinical outcome [6].
However, a residual more than mild aortic regurgitation was more
frequently observed in patients treated with CV than those treated
with balloon-expandable valves [1], with a reported impact on patient
prognosis [9]. Therefore, the 2nd generation EVR valve was recently
released with a new design and delivery system aimed to facilitate the
implantation process and to reduce paravalvular leaks. Important new
features of the EVR bioprosthesis include the option to recapture and
reposition the valve during deployment, an extended sealing skirt,
more consistent radial forces of the nitinol frame and a smaller insertion
proﬁle.Fig. 2. Degree of residual aortic regurgitation after TAVI as assessed by transthoracic
echocardiography (left columns) or aortic root angiography (right columns).In our initial experience patient population, the option to recapture
was used in 22.1% of the EVR implantation procedures, mainly due to
a deep position of the prosthesis in the left ventricular outﬂow tract.
This maneuver may prevent suboptimal valve deployment and allows
delivery of the prosthesis at the intended position 3–5 mm below the
native annulus. This was achieved in a real life scenario, as the average
implantation depth at the non-coronary cusp was 4.0 mm for the EVR
and slightly deeper with the CV prosthesis (average 5.3 mm). Even
more important, supra-annular valve deployment happened in 2
patients treated with CV but was absent in the EVR group as a result
of the recapture option.
As a possible consequence of less implantation depth, the EVR
prosthesis had a lower incidence of moderate aortic regurgitation
assessed by angiography, transthoracic echocardiography and aortic
regurgitation index. Other features such as the extended sealing skirt
or more consistent radial force may have contributed to this observa-
tion. In addition, the cover index was higher in the EVR as compared
to the CV group, indicating a higher degree of prosthesis oversizing
that may also increase the ability of the prosthesis to seal the native
annulus.
On the other hand, oversizing may result in incomplete expansion
and higher transvalvular gradients after implantation, which were in-
deed observed in EVR treated patients. The difference in postprocedural
transvalvular gradients was particularly evident in the invasive record-
ings immediately after implantation. Since the nitinol frame of both
prostheses exerts continuous radial force towards the annulus and
adjacent structures, it may be that – particularly in patients with a
more “oversized” annular-prosthetic ratio – smaller changes of
prosthetic apposition occur during the ﬁrst hours after implantation.
This may explain why the gradients determined by echocardiography
between days 2 and 5 after the procedure only show a smaller (albeit
still statistically signiﬁcant) difference. Most importantly, mean
postprocedural gradients were within or even below the “normal”
range of published mean TAVI transprosthetic gradients [11] (CV
6.9 ± 0.4 mm Hg, EVR 8.3 ± 0.4 mm Hg) and they were compatible
with normal prosthetic function according to the VARC-2 criteria
(mean gradient b 20 mmHg). In addition, no events of annular rupture
or other harmful effects possibly related to prosthesis oversizing were
observed. To our knowledge, no data are available to date on whether
differences in transvalvular gradients within the normal range may
affect clinical outcomes. Since in our study the differences in hemody-
namic gradients are small and were even less pronounced in
postprocedural echocardiography, we believe that these ﬁndings are
of minor clinical importance.
Another important progress with EVR was the smaller insertion
proﬁle of 18F outer diameter (inline sheath of the EVR delivery system)
as compared to 22F outer diameter for the 18F sheath generally used for
CV implantation. Smaller sheath sizes will automatically decrease the
56 E. Schulz et al. / IJC Heart & Vasculature 12 (2016) 52–56sheath to the femoral artery ratio, which was associated with fewer
vascular complications in a previous study [3]. However, the smaller in-
sertion proﬁle of the EVR allows transfemoral access in more challeng-
ing anatomies. In our patient subset, vascular complications and
sheath/femoral artery ratio were comparable between groups despite
a smaller entry vessel diameter in the EVR group, indicating that
patients treated with EVR had a more challenging iliofemoral vessel
anatomy. Whether the relatively low observed rate of vascular compli-
cations justiﬁes the additional radiation and contrast exposure
necessary for the routine placement of a crossover safety wire is open
to discussion.
Amajor downside of TAVI is the frequent need for permanent pacing
after the procedure, as valve expansion (required for a stable valve
position) may lead to mechanically induced conduction disturbances.
The CV system had higher rates of post-procedural permanent
pacemaker implantations when compared to balloon-expandable
valves, mostly owing to an unintended deep positioning of the self-
expandable nitinol frame. Although the recapture option of the EVR
prosthesis prevented deep valve deployment also in our study, this
had no impact on the incidence of new permanent pacemaker implan-
tation due to asystole or third degree AV block. However, it has to be
noted that the implantation depth of the CV in our study was only
5.3 mm on average, which is clearly a higher implantation approach
than the 9.9 mm reported in earlier studies [9]. Another factor that
may affect pacemaker rate is the degree of oversizing [7]. Since EVR
treated patients in our study had a higher cover index (Table 3), this
may have increased the need for permanent pacing.
4.1. Limitations
The single-center observational retrospective analysis of 151 con-
secutive patients undergoing transfemoral self-expandable TAVI report-
ed here cannot be considered as a true head-to-head comparison of the
two TAVI systems. Albeit multimodal, the assessment of post-TAVI
aortic regurgitation was not performed by core laboratory evaluation.
The number of patients treated and the lack of longer-term follow-up
to date do not allow for conclusions on clinical outcomes or the inci-
dence of rare complications. However, in the evolving ﬁeld of interven-
tional heart valve therapy and inherent technical innovations, such
observational data reﬂecting initial experience in “real world” patients
provide valuable timely clinical information. Additional larger scale
multi-center evaluation comprising a longer follow-up period will
have to assess the potential clinical differences of EVR and CV observed
in the present analysis.
5. Conclusions
The recapture option of the Medtronic EVR transcatheter
bioprosthesis leads to a signiﬁcantly higher rate of device success and
a lower implantation depth as compared to the preceding CV system.
Together with an extended sealing skirt and more consistent radial
forces, this feature of EVR prevented the incidence of more than mild
residual aortic regurgitation more efﬁciently in an all-comer clinical
setting. The rates of vascular complications as well as post-procedural
pacemaker implantation were similar and need to be addressed in
larger scale clinical studies.
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